Transcatheter Aortic Valve Replacement (TAVR) is a new option for the treatment of aortic stenosis, a common heart problem affecting approximately 1 million patients in the U.S. each year. Although surgical aortic valve replacement is the gold standard for the treatment of severe aortic stenosis, 60 percent of patients are too high-risk to undergo traditional surgery.
TAVR, an innovative minimally invasive option for these high-risk patients, was approved by the Food and Drug Administration in November 2011. In 2005, Beaumont was the first hospital in North America to perform this procedure and currently is one of only a few centers in Michigan to offer TAVR.
To connect to a heart and vascular specialist or to schedule an appointment, call 800-633-7377.